ArticleClinicoEconomics and outcomes research : CEOR2019

Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA.

L K Billings et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.